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Resumo 
 
 
Eritrocitose Congénita (EC) designa um grupo de patologias que podem ser 
primárias ou secundárias, sendo classificadas com base nos níveis de 
eritropoietina (EPO). A EC primária, devida a alterações nos percursores 
eritroides, é causada por alterações no recetor da eritropoietina (EpoR) 
devido a mutações nos genes EPOR e SH2B3. O EpoR fica 
permanentemente ativado, o que leva à diminuição dos níveis de EPO. A 
EC secundária pode ser causada por alterações de componentes na via de 
sensibilização ao oxigénio, devido a mutações nos genes VHL, EGLN1 e 
EPAS1, ou devido a hemoglobinas de alta afinidade para o oxigénio em 
consequência de mutações nos genes HBA, HBB e BPGM. Mutações nestes 
genes promovem um aumento dos níveis de EPO. Apesar de já estarem 
descritas causas moleculares para a origem da EC, cerca de 70% dos 
doentes ainda permanecem sem uma causa genética identificada. 
 
Neste estudo foram analisadas 125 amostras de indivíduos com suspeita 
de EC, seguidos no Centro Hospitalar e Universitário de Coimbra ou 
enviados de outros hospitais portugueses/internacionais. Os testes 
laboratoriais foram orientados com base na história clínica e familiar e nos 
níveis de EPO, e incluíram a sequenciação dos genes: EPOR, SH2B3, VHL, 
EGLN1, EPAS1, HBA, HBB, BPGM. 
Foram identificadas 5 mutações: 3 no gene VHL (c.74C>T, p.Pro25Leu; 
c.154G>T, p.Glu52*; c.241C>T, p.Pro81Ser), 1 no gene EGLN1 (c.1216G>C, 
p.Gly406Arg) e 1 no gene HBB (Hb San Diego [HBB: c.328G>A, 
p.Val110Met]). Mutações no gene VHL têm uma transmissão autossómica 
recessiva estando descritos casos esporádicos em que se encontra apenas 
uma mutação, também neste estudo todas as mutações encontradas estão 
em heterozigotia. O mecanismo subjacente nestes casos ainda permanece 
por elucidar. A mutação encontrada no gene EGLN1 não está descrita na 
literatura, segundo a análise in sílico é uma variante patogénica, pelo que 
deverá ser a causa da EC. No gene HBB a variante foi identificada num 
individuo de origem turca, sendo a primeira descrição desta variante na 
Turquia.  
Concluindo, neste estudo foi possível identificar a causa molecular da EC 
em 5/125 doentes estudados. Foram encontradas 4 mutações descritas e 1 
nova mutação. No entanto, 120 doentes ainda permanecem sem 
diagnóstico molecular. Isto demonstra que mais estudos são necessários 
para entender esta doença. O uso da tecnologia de Next Generation 
Sequencing (NGS) pode ser uma ferramenta valiosa no estudo da EC, uma 
vez que pode identificar outros genes que possam estar envolvidos na EC. 
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Abstract 
 
 
Congenital Erythrocytosis (CE) belongs to a diseases group that can be 
primary or secondary, and are classified based on EPO levels. Primary CE, 
due to mutations in the erythroid precursors, is caused by changes in EPO 
receptor (EpoR) due to mutations in EPOR and SH2B3 genes. EpoR is 
permanently activated, which leads to a decrease in EPO levels. Secondary 
CE can be caused by defects in the components of the oxygen-sensing 
pathway, namely mutations in VHL, EGLN1 and EPAS1, or due to congenital 
defects such as Hbs with increased oxygen affinity, due to mutations in the 
HBB, HBA or BPGM. Mutations in these genes leads to an increase of EPO 
levels. Despite important discoveries in the molecular pathogenesis of CE, 
in about 70% of the patients the genetic causes remain to be identified. 
In this study were analysed 125 samples of individuals with suspicious of 
CE, followed in Centro Hospitalar e Universitário de Coimbra or from other 
Portuguese/international hospitals. Laboratory testing was guided by 
clinical  and familiarhistory and EPO levels, and included: EPOR, SH2B3, 
VHL, EGLN1, EPAS1, HBA, HBB, BPGM sequencing. 
Were identified 5 mutations: 3 in VHL gene (c.74C>T, p.Pro25Leu; 
c.154G>T, p.Glu52*; c.241C>T, p.Pro81Ser), 1 in EGLN1 gene (c.1216G>C, 
p.Gly406Arg) and 1 in HBB gene (Hb San Diego [HBB: c.328G>A, 
p.Val110Met]). Mutations in VHL gene have an autosomal recessive 
inheritance, with sporadic cases in which only one mutation is found, also 
in this study all the mutations found are in heterozygosity. The underlying 
mechanism in these cases still remains to be elucidated. The mutation 
found in the EGLN1 gene is not described in the literature, according to in 
silico analysis it is a pathogenic variant and should therefore be the cause 
of CE. In the HBB gene the variant was identified in an individual of Turkish 
origin, the first description of this variant in Turkey 
In conclusion, in this study was possible to identify the CE molecular 
aetiology in 5/125 patients studied. It was found 4 described mutations and 
1 new mutation. However, 120 patients still remain without molecular 
diagnosis. This demonstrates that more studies are needed to understand 
this disease. The use of Next Generation Sequencing (NGS) technology can 
be a valuable tool in the study of CE as it can identify other genes that may 
be involved in CE. 
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1. Erythrocytosis 
1.1 General Overview 
 The supply of oxygen (O2) to the tissues is accomplished by red blood cells (RBC) containing 
haemoglobin (Hb). Hb is an iron-containing molecule in the blood that is responsible to transports 
oxygen to tissues. The membrane of RBC is rich in proteins and lipids, which confer essential 
characteristics for physiological function  such as deformability and stability (1). Due to the lack of 
the nucleus in the mature RBC, the storage capacity of Hb is increased. The production of these 
cells is maintained through mechanisms of homeostasis, such as vasoconstriction or coagulation 
(1,2). However, any imbalance in these mechanisms may lead to an increase in the production of 
RBC, causing pathologies namely as erythrocytosis (1,3).  
 Erythrocytosis is a rare disease characterized by a high haematocrit (Hct), increased levels 
of Hb and an increase in the number of RBC when compared with the reference values for normality 
(3,4,5). These values vary according to gender, age and living altitude. Erythrocytosis is diagnosed 
when values measured in adults are as follows: Hb> 18.5 g/dL or Hct> 52% in men and Hb> 16.5g/dL 
or Hct> 48% in women (6). Due to an increase in the number of RBC, this disorder leads to the 
increase blood viscosity which may lead to the emergence of symptoms, such as headaches, 
dizziness and/or pruritus after bathing. The most common strategy applied to alleviate these 
symptoms has been to perform regular phlebotomies. This technique consists of the periodic 
collection (usually every 3 months) of a certain volume of blood (about 500 mL), with the purpose 
of decreasing the Hct (2).  
1.2 Classification of Erythrocytosis 
 Erythrocytosis is first classified based on levels of erythropoietin (EPO), the hormone that 
regulates the production of RBC. EPO is produced primarily in the kidney, and in lesser amounts in 
the liver, and circulates freely in the blood (7,8,9). Hypoxia (blood oxygen deficiency) is one of the 
main stimuli for EPO production. On suspicion of erythrocytosis, low levels of EPO are associated 
with primary erythrocytosis, while normal to high levels are associated with secondary 
erythrocytosis. However, individuals without erythrocytosis can also show low/high levels of EPO 
(8). 
 Primary erythrocytosis occurs due to intrinsic defects in erythroid precursors, namely 
proerytroblasts and erythroblasts, among others, which reflect the low levels of EPO and the 
hypersensitivity of erythroid precursors to EPO (5). On the other hand, secondary erythrocytosis 
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manifests through increased production of EPO for unknown reason, or due to tissue response to 
hypoxia. This increment in EPO production occurs through causes extrinsic to the erythroid 
precursors, such as hypoxia, thus promoting a higher production of RBC (5,10). 
 In addition to evaluating EPO levels, it is important to unravel the underlying cause of 
erythrocytosis, which can be congenital or acquired (3). The latter is the most frequent forms of 
erythrocytosis and should be first excluded. This also occurs in renal, cardiac, hepatic and 
pulmonary diseases, leading to an increase of EPO, and also due to hepatoma, haemagioblastoma, 
nephroblastoma, endocrine and uterine tumours, and polycythaemia Vera, which may cause 
autonomic synthesis of EPO (3,15,16,17). All of the aforementioned conditions are associated with 
normal to high levels of EPO, except for polycythaemia Vera, which is associated with low levels of 
EPO (11,17,18). Polycythaemia Vera is a clonal form of primary erythrocytosis and its usually 
associated with Janus kinase (JAK2) mutations (JAK2 V617F or exon 12) (19,20). Finally, people living 
at high altitudes also show a high number of RBC, due an increase of EPO, which is classified as an 
acquired cause since it is triggered due to external factors (13). 
 Congenital erythrocytosis (CE) is an inherited disease that is present since birth. Germline 
mutations result in the translation of defective proteins, either the regulation of EPO and its 
receptor (EpoR) or in the oxygen sensing pathway, both leading to an increase of RBC. Additionally, 
CE may be either primary or secondary depending on the mutated gene, and as a consequence of 
these mutations, EPO levels are affected (3,5,12). Primary CE is associated with low levels of EPO 
and hypersensitivity of erythroid precursors to EPO, and is only found in 12% of the patients with 
an identified molecular cause (14). The usual known form is caused by mutations in the EPOR gene, 
and more recently mutations in SH2B3 gene, which encodes the lymphocyte adaptor protein (LNK), 
were described (14,22,23,24).  
 On the other hand, secondary CE is associated with an increase of EPO levels which may 
arise due to defects in the components of the oxygen sensing pathway, namely mutations in prolyl 
hydroxylase domain-containing protein 2 (PHD2, encoded by EGLN1 gene), hypoxia-inducible factor 
2α ( HIF2α, encoded by EPAS1 gene) and von Hippel Lindau protein (VHL, encoded by VHL gene) 
(13,16,22,25). Additionally, secondary CE can be related to Hb variants with high oxygen affinity, 
due to mutations in the beta (β) or alpha (α) globin genes (HBB, HBA) or due to a 2,3 
bisphosphoglycerate (2,3-BPG) deficiency, that result from mutations in the BPGM gene. High 
oxygen affinity Hbs  causes tissue hypoxia, and promotes a higher production of RBC (8,26,27,28).  
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 Finally, when the cause of erythrocytosis is still elusive after extensive testing, it is classified 
as Idiopathic Erythrocytosis. This corresponds to the majority of cases suspected of having 
erythrocytosis (17). Table 1 summarizes causing mutations of erythrocytosis. 
Table 1- Classification of Erythrocytosis and causing mutations. 
 
2. Congenital Erythrocytosis- Molecular Mechanisms 
 Nowadays there are 8 genes described as associated with CE, which are the following: 
EPOR, SH2B3, VHL, EGLN1, EPAS1, BPGM, HBB e HBA (13). Low levels of EPO are indicative of 
defects in EPO signalling pathway, unlike the normal to high levels, which are indicative of defects 
in the oxygen sensing pathway or are related to Hb variants with high oxygen affinity. The various 
genes involved in this pathology are associated with the different types of CE and different types of 
inheritances  (12,13,27,30). These characteristics are shown in table 2. 
 
Primary ( ↓levels of EPO) Secondary (↑ levels of EPO) 
Congenital Acquired Congenital Acquired 
Congenital 
Erythrocytosis type 1 
(ECYT1)- due to 
mutations in EPOR and 
SH2B3 
Polycythaemia Vera 
(PV) – due to 
JAK2V617F and JAK2 
exon12 mutations 
Hb with high affinity to 
O2 – mutations in HBB 
and HBA and 
deficiency in 2,3-BPG- 
mutations in BPGM 
Increase of EPO due to: 
-Cardiac, pulmonary, liver 
and kidney diseases 
Autonomous EPO synthesis 
caused by: 
- nephroblastoma 
- hepatoma 
- haemagioblastoma 
- Endocrine tumour 
- Uterus tumour 
Congenital 
Erythrocytosis type 2 
(ECYT2)- mutations in 
VHL 
Congenital 
Erythrocytosis type 3 
(ECYT3)- Mutations in 
PHD2 (EGLN1) 
Congenital 
Erythrocytosis type 4 
(ECYT4)- Mutations in 
HIF2α (EPAS1) 
Idiopathic- unknown molecular cause 
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Table 2- Congenital Erythrocytosis- Disease group, gene, location, number of exons, inheritance, and proteins 
related to genes involved in Congenital Erythrocytosis (5). 
DISEASE GROUP 
(OMIM NUMBER) 
GENE 
(OMIM NUMBER) 
LOCATION 
NUMBER 
OF 
EXONS 
INHERITANCE PROTEIN 
ECYT1 
(133100) 
EPOR 
(133171) 
19p13.2 8 
Dominant 
(de novo cases 
described) 
EPO receptor 
(EpoR) 
SH2B3 
(605093) 
12q24.12 8 - 
Lymphocyte 
adaptor protein- 
LNK 
ECYT2 
(263400) 
VHL 
(608537) 
3p25.3 3 
Recessive 
(dominant 
cases 
described) 
von Hippel Lindau 
protein - VHL 
ECYT3 
(609820) 
EGLN1 
(606425) 
1q42.1 5 Dominant 
Prolyl hydroxylase 
domain-containing 
protein 2- PHD2 
ECYT4 
(611783) 
EPAS1 
(603349) 
2p21 16 Dominant 
Hypoxia Inducible 
Factor 2α - HIF-2α 
HIGH OXYGEN 
AFFINITY: 
HBA(-), HBB (-) 
BPGM 
(222800) 
HBA 
(HBA1/HBA2) 
(141800), 
HBB 
(141900) 
11p15.4 
16p13.3 
3 
3 
Dominant Haemoglobin- Hb 
BPGM (613896) 7q33 2 Recessive 
Biphophoglycerate 
mutase- BPGM 
 
2.1 Primary Congenital Erythrocytosis 
2.1.1 ECYT1- EpoR (EPOR gene) and LNK (SH2B3 gene) 
 Primary CE is usually characterized by low levels of EPO, hypersensitivity of erythroid 
precursors to EPO and normal oxygen affinity of Hb. Typically, it occurs due to an autosomal 
dominant inheritance, arising from mutations in the EPOR gene that result in a protein 
constitutively active, or from mutations in LNK, which is a negative regulator of the cytokine 
signalling pathway (14).  EPO is a cytokine that binds to EpoR which is a homodimer present on the 
cell surface of erythroid cells. The binding of EPO to EpoR initiates a phosphorylation cascade 
signalling pathway involved in proliferation, differentiation and prevention of apoptosis (13). The 
most common mutations in EPOR gene are nonsense and are located in exon 8, which is responsible 
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for encoding the C-terminal negative regulatory domain of the protein. Mutations in this exon 
results in a truncated protein (14,18,19).  
 As shown in figure 1, upon binding of EPO to EpoR, homodimerization of EpoR occurs and 
leads to autophosphorylation of the associated tyrosine JAK2. Activation of JAK2 protein mediates 
a signalling cascade that lead to the phosphorylation of tyrosine residues in the cytoplasmic domain 
of the EpoR, which serves as a docking site for the signal transducer and as an activator of 
transcription 5 (STAT5) protein, the adaptor molecule growth factor receptor protein 2 (Grb2) and 
phosphatidylinositol 3-kinase (PI3K). Activated STAT5 homodimerizes and is translocated to the 
nucleus where it binds to the promoter of target genes, and thus EPOR gene transcription is 
initiated. Cell proliferation is supported by the activation of Ras/mitogen associated protein 
(Ras/MAP) kinase through Grb2. In addition, activation of PI3K results in the phosphorylation of Akt 
and the induction of several anti-apoptotic proteins, such as Bcl-2, Bclx and protein kinase B, thus 
prolonging cell survival increasing proliferation and inhibiting apoptosis (20).  
 
Figure 1- Representation of the EPO signalling and JAK/STAT pathway. 
EPO binds to its receptor (EpoR) and autophosphorylates, JAK2 dimerises STAT5 that is translocate into the 
nucleus where it binds to the promoter of target genes. After the binding of EPO to EpoR all signalling 
pathways are disrupted by the attenuation of JAK2 activation. LNK through its SH2 domain negatively 
modulates EpoR signalling by attenuating JAK2 activation and regulates EPO-mediated erythropoiesis. 
Adapted from (13,21,22). 
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 Several different mechanisms are activated to control the EPO responsiveness of erythroid 
cells so they can tightly regulate and thus prevent uncontrolled erythropoiesis. As a result, around 
30 minutes after EPO binding all signalling pathways are disrupted by the attenuation of JAK2 
activation (21). Inhibitory proteins are recruited to the receptor, such as the phosphatase SHP-1, 
which is responsible for the dephosphorylation of EpoR and JAK2 (21). Furthermore, STAT5 induces 
the transcription of several members of the suppressors of cytokine signalling (SOCS) proteins and, 
in particular, cytokine-inducible SH2-domain-containing protein (CISH) and SOCS3. CISH is able to 
bind phosphorylated tyrosines residues on the EpoR thus blocking the association of STAT5 to the 
receptor. Finally, the role of SOCS3 is to disrupt signalling by targeting the EpoR for ubiquitin 
mediated proteasomal degradation (13,20,21,23). 
 The LNK, a negative regulator of the cytokine signalling, is comprised of a proline-rich N-
terminal dimerization domain, a pleckstrin homology (PH) domain, a Src homology 2 (SH2) domain, 
and a conserved C-terminal tyrosine residue. LNK  negatively modulates EpoR signalling through its 
SH2 domain by attenuating JAK2 activation and moreover regulates EPO-mediated erythropoiesis 
(13,21). In the presence of EPO, LNK becomes phosphorylated and is able to block the three 
important signalling pathways of JAK/STAT, phosphoinositide-3 kinase (Pi3 kinase/AKT) and 
mitogen-activated protein kinase (MAPK) (21). Figure 1 shows the representation of the EPO 
signalling and JAK/STAT pathway. 
CE mutations found in EPOR gene lead to a premature stop codon and hence result in a 
truncated receptor that lacks the negative regulatory domain. The most common mutations in 
EPOR gene are nonsense and are usually located in exon 8.  As a consequence, there is loss of the 
docking site in SHP-1 and for that reason, when EPO binds to EpoR, the receptor is switched on, but 
does not get switched off again  (13,21). Thus, there is continuous stimulus that drives to an 
increase of RBC production (13,20).  
On the other hand, primary CE can also be due to missense mutations in SH2B3 gene, which 
encodes the LNK protein. Although mutations in SH2B3 gene are usually described in association 
with myeloproliferative neoplasms, there are a few cases of primary CE associated with mutations 
in this gene (13,18). As mentioned before, LNK is a negative regulator of the cytokine signalling by 
attenuating JAK2 activation and consequently EPO mediated erythropoiesis. Mutations in SH2B3 
gene results in a defective LNK protein that does not act as a negative regulator of the JAK/STAT 
pathway downstream of the cytokine attachment to its receptor and thus lead to increased 
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downstream erythropoiesis and primary erythrocytosis (with an associated low EPO levels) 
(13,18,24).  
2.2 Secondary Congenital Erythrocytosis 
2.2.1 Oxygen sensing pathway- Molecular Mechanisms 
 Oxygen sensing is a fundamental and essential biological process for the survival of all 
organisms. Under hypoxia conditions, the oxygen sensing pathway is activated and involve three 
important proteins- VHL, PHD2 and HIF2α- which are responsible for the regulation of EPO gene. In 
normal conditions (normoxia) oxygen activates propyl hydroxylases (PHDs) which catalyse the 
hydroxylation of HIF, comprised of an alpha and a beta subunit. PHDs hydroxylated propyl residues 
located within the HIFα allow the binding of HIFα to the VHL protein. This binding induces 
ubiquitination, which targets them for proteasomal degradation, in normoxia conditions. However, 
a reduction of the oxygen levels leads to a hypoxia state under which HIFα is stabilized due to the 
decrease of its hydroxylation.  This leads to translocation of HIFα into the nucleus, where it binds 
to the subunit HIFβ, both forming an active heterodimer, which then binds to hypoxia responsive 
elements within the genome. This event leads to the activation of target genes and increased 
production of proteins such as EPO (figure 2).  
  
Figure 2- Oxygen-sensing pathway. 
In normoxia condition the alpha subunit of hypoxia inducible factor 2α (HIF2α) is hydroxylated by propyl 
hydroxylase domain-containing protein 2 (PHD2) and binds the VHL protein (pVHL). This process induces the 
ubiquitination of HIF2α in the proteasome. In hypoxia, HIF-2α is stabilized and translocated into the nucleus 
where binds to the β subunit, which causes the production of a number of target proteins including EPO. 
Based on (13). 
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2.2.1.1 ECYT2- VHL (VHL gene) 
 VHL gene has two translational initiation sites- +1 and +54- that encode two proteins, 
pVHL30 (larger) and pVHL19 (shorter), respectively. Both are functional proteins and allow the 
binding of HIFα (25). The first mutation described in the oxygen sensing pathway was in the VHL 
gene. This mutation was identified in a large cohort of individuals with erythrocytosis in the Chuvash 
region of Russia. Chuvash polycythaemia is an endemic disorder, characterized by normal or 
elevated EPO levels and inheritance is autosomal recessive and due to homozigoty for c.598C>T, 
p.Arg200Trp (R200W) mutation in VHL gene that results in a lost-of function mutation 
(13,15,26,27). It was shown that the mutant protein had reduced activity as a negative regulator of 
HIF gene transcription, resulting in increased expression of HIF, and thus target genes including EPO 
(27). Later, this mutation was identified in other countries, such as England, Pakistan and most 
recently in the Italian island of Ischia (28,29). 
 CE due to mutations in VHL gene is a recessive disease, but the occurrence of individuals 
heterozygous for VHL mutations with CE has been described.  For example, the mutation 
p.Arg200Trp, firstly found in homozygous state in Chuvash patients and also identified in 
combination with other VHL mutations (compound heterozygosity), was also described in CE 
patients only in the heterozygous state in association with CE type 2 (5,30). However, it is not clear 
in these cases how erythrocytosis results. So, further investigation into the genome must be carried 
out, with the aim of identifying new mutations or polymorphisms in association with described ones 
may be causing the symptoms (9). The symptoms of CE type 2 are usually flushing, low blood 
pressure, stroke and thrombotic events, varicosities and haemangiomas (15).  
2.2.1.2 ECYT3- PHD2 (EGLN1 gene) 
 There are three PHD isoenzymes (PHD1, PHD2 and PHD3), but PHD2 is the key enzyme that 
site-specifically modifies HIF2α in an oxygen-dependent manner, in normoxia conditions (5). Loss-
of-function mutations in EGLN1 gene result in a mutant PHD2 and have an autossomal dominant 
inheritance. So, erythrocytosis occurs due to the decreased binding ability of the PHD2 and 
subsequent increased activity of HIFα (25,40).  
 The first mutation described was the heterozygous mutation c.950C>G, which results in a 
p.Pro317Arg substitution in a highly conserved region of the protein and was described in three 
individuals from two generations of the same family (two of them were siblings). All had 
erythrocytosis with normal to elevated EPO levels in contrast to the normal individuals (5,34). 
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Another family with a PHD2 mutation resulting in an p.Arg371His substitution showed gain of 
function of the PHD2 activity in vitro (35).  
2.2.1.3 ECYT4- HIF2α (EPAS1) 
 The transcription factor HIF2α is hydroxylated by the PHD2 and then degraded by VHL 
protein. The HIFα factor has three isoforms (HIF1α, HIF2α and HIF3α), but HIF2α is the principal 
transcription factor that induces the EPO expression, under hypoxia conditions (36). In contrast to 
loss-of-function mutations described for VHL and EGLN1 genes, mutations in EPAS1 gene lead to a 
gain-of-function of HIF2α, meaning that the protein is continuously bound to HIFβ, promoting the 
EPO gene transcription. These mutations have an autosomal dominant mode of inheritance (5,36).   
 A family with erythrocytosis and elevated EPO levels in three generations was found to have 
a mutation in the oxygen degradation domain of HIF2α resulting in a Gly537Trp substitution. In vitro 
studies showed that the mutation affects hydroxylation of HIF2α by PHD2 and subsequently the 
recognition of HIF2α by the VHL protein (37). Other HIF2α missense mutations have been described 
(Pro534Leu, Met535Val, Met535Ile, Met535Thr, Gly537Trp, Gly537Arg, and Phe540Leu) close to 
the primary site of hydroxylation Pro531 of HIF2α. In general, these patients had dominant 
erythrocytosis with normal or raised EPO levels and in some cases, a history of thrombosis or 
pulmonary hypertension (9,36–39).    
2.2.2 High oxygen affinity variants of Haemoglobin   
 Hb is a tetramer comprised of two alpha and two beta globin chains and four heme groups, 
each one having a porphyrin ring that contains an iron (Fe) atom in the centre and where oxygen 
binds reversibly (40). There are two protein conformations that present  different oxygen affinities: 
tense (T) and relaxed (R) with low and high oxygen affinity, respectively, and the existing  
equilibrium between them is readily observable in the oxygen dissociation curve (figure 3) 
(13,41,42). Oxygen affinity can vary because of several factors, such as blood pH, levels of 2,3-BPG, 
haemoglobin structure and temperature.  An increase of carbon dioxide (CO2) leads to a decrease 
of the pH, and then a decrease of the oxygen affinity, allowing the delivery of O2 to the tissues 
(40,42).  
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Figure 3- Oxygen dissociation curve. 
In red is represented a shift to the right (decreased oxygen affinity) and in blue is represented a shift to the 
left (high oxygen affinity). Variations of 2,3- biphosphoglycerate mutase (2,3-BPG), CO (carbon monoxide), 
CO2 (carbon dioxide), temperature, pH and high oxygen affinity haemoglobins are responsible for the shift of 
the oxygen dissociation curve (21). 
2.2.2.1 HBA and HBB genes  
 The α and β chains of Hb are encoded by HBA and HBB genes respectively. Due to the 
duplication of the HBA gene, there are two genes- HBA1 and HBA2 (13,43). Hb Chesapeake was the 
first mutation described in these genes, and results from a leucine to arginine substitution at 
position 92 in the α-chain (HBA gene). The latter was found in an 81-year-old man and, after a family 
study, was identified in other fifteen familiar members. The oxygen dissociation curve showed a 
shift to the left, typical of high oxygen affinity haemoglobins (44). 
 Currently, there are more than 100 high oxygen affinity variants described for these genes, 
the most frequent being associated with the HBB gene. Transmission in affected patients is usually 
autosomal dominant (45).  Most of the high-affinity variants described thus far have substitutions 
at one of three regions that are crucial for haemoglobin function: (1) the α1β2 interface; (2) the C-
terminal end of the β-chain; and (3) the 2,3-BPG binding site (5). Individuals diagnosed with high 
affinity Hb tend to be asymptomatic and have high Hct, which is results in hyperviscosity (21).   
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2.2.2.2 BPGM gene 
 The enzyme biphosphoglycerate mutase (BPGM) is responsible for the conversion of 1,3 
bisphosphoglycerate (1,3-BPG) to 2,3 bisphosphoglycerate (2,3-BPG) and regulates the affinity of 
Hb to oxygen through 2,3-BPG levels. The affinity of Hb to oxygen decreases by the binding of 2,3-
BPG, which results in a shift in the oxygen affinity curve to the right, and thus the oxygen is delivered 
to the tissues (16). Mutations in BPGM gene are extremely rare and lead to a decrease of 2,3-BPG 
levels that consequently causes a shift in the oxygen affinity curve to the left. To balance the 
decrease of oxygen that is delivered to the cells, there is an increase in the production of RBC, and 
thus erythrocytosis  (13,16).  Autosomal and recessive cases have been associated with mutations 
in BPGM gene (46).  
3. Diagnosis and Treatment  
 A correct diagnosis is crucial where there is suspicion of erythrocytosis. For this reason, and 
as mentioned in section 1.2, acquired causes need to be first excluded (10,47,48). It is also 
important to screen for conditions like splenomegaly, thrombocytosis and leucocytosis  whose 
presence excludes the possibility of CE (48). The first steps in the screening for CE should be 
gathering information on the family history and determining serum EPO levels. This information is 
important for the decision of which molecular tests must be done and in which order. When 
possible, the determination of P50 and the evaluation of the presence of high oxygen affinity 
variants of Hb are recommended (10,47,48).  
 Nowadays, with the introduction of the Next Generation Sequencing (NGS) technique it is 
possible to perform a more complete and detailed analysis of several genes simultaneously. 
Moreover, it should be noted that sequencing of the genes associated with erythrocytosis is 
mandatory for the final diagnosis (5,47,49).  The most recent diagnostic algorithm was established 
by members of MPN&MPNr-Euronet, a network of experts in the molecular diagnosis of 
myeloproliferative neoplasms and congenital diseases, and is based on the determination of EPO 
levels and p50 (10,47). 
 The first line of treatment to erythrocytosis has been phlebotomy, with the purpose of 
maintaining the value of haematocrit below 0.45. However, low doses of aspirin are also sometimes 
given in order to decrease the occurrence of possible thrombotic events (10,48). 
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The main goals of this project are: 
 Identification of mutations associated with CE through molecular studies, in a group of patients 
with unknown cause of CE, followed in Serviço de Hematologia Clínica do Centro Hospitalar e 
Universitário de Coimbra (SHC-CHUC), during the last two years; 
 Develop skills on molecular techniques as DNA extraction, polymerase chain reaction (PCR) and 
Sanger sequencing; 
 Prediction of the pathogenicity of the mutations found, using in sílico tools; 
 Update of the online databases and literature.  
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1. Analysis of blood samples 
The blood samples used in this study were from patients followed in SHC-CHUC or referred 
from other Portuguese or international hospitals. Studied patients were mainly male and from 
Portugal (one hundred and eleven samples were from Portugal, six samples were from Turkey, one 
from Italy and seven from Spain). Molecular studies were performed in the laboratory of the 
Erythrophatology and Iron Metabolism Unit, SHC-CHUC.  
  Molecular studies consisted of DNA extraction, amplification of DNA through PCR, agarose 
gel electrophoresis to confirm the amplification of DNA and Sanger sequencing. Laboratory tests 
were guided by the clinical and familial history and EPO levels and include Sanger sequencing of the 
genes: EPOR (exons 7 and 8), SH2B3 (all gene), VHL (all gene), EGLN1 (all gene), EPAS1 (exon 12), 
BPGM (all gene), HBB (all gene) and HBA (all gene). New mutations were analysed by in sílico 
analyses to classify its pathogenicity.  
 DNA Extractions 
 DNA was extracted from blood samples collected in EDTA, using the following DNA 
extraction kit: QIAamp® DNA Blood and PureLink™ gDNA Blood. The DNA extractors used were 
QIAcube 10600® (QIAGEN) and iPrep™ (Invitrogen). 
 Amplification of DNA by PCR 
 The main goal of PCR it was obtain a high number of fragment copies of the specific genes 
to increase the DNA amount. For each gene, different PCR reaction were made and for all PCR 
reactions were used 2µL of DNA. The thermocycler used in the PCR reactions was the BioRad 
C1000™ Thermal Cycler and the reagents were from QIAGEN®. PCR reactions and primers for the 
genes studied are in annex I.  
 Agarose Gel Electrophoresis 
 The amplification of DNA by PCR was confirmed in a 2% agarose gel. This gel was prepared 
with 1g of agarose mixed in 50mL 0.5% TBE (Tris 1.78M; EDTA 0.04M; Boric Acid 1.77M). The 
solution was heated until the agarose was completely dissolved, and then were added 4µL of SYBR™ 
Safe. 4µL of PCR samples was load into the gel mixed with a drop of loading dye. Finally, the gel was 
run at 120V for 25 minutes. At the end of the run, DNA fragments were visualized with UV light and 
photographed.  
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 HPLC 
 High-Performance Liquid Chromatography (HPLC) was performed in the Premier 
Hb9210 resolution for the analysis of Hb variants and quantification of Hb A2 and Hb F.  This analysis 
was performed through the ion-exchange column that has been equilibrated with respect to pH 
and ionic the hemoglobin species.   
 Sanger sequencing of the genes 
 Purification of the PCR products by EXOSAP® 
 The purification of PCR samples it was performed with EXOSAP®. First, it was made a 
digestion of: primers, Taq polymerase, amongst others compounds of the PCR reaction, except DNA 
double strand. To that, it was added 0.75µL of EXOSAP® to 3µL of sample. Then, purification it was 
performed in a thermocycler in to steps, which are the following: 15 minutes at 37°C and 15 minutes 
to 80°C.  
 Sequencing and precipitation reaction  
 The sequencing reaction of the purified PCR products was performed by BigDye® 
Terminator v1.1 Cycler Sequencing (Applied Biosystems, Carlsbad, CA, USA) kit. This kit contains a 
buffer, DNA polymerase, dNTP’s and ddNTP’s marked with 4 different fluorochromes. The 
sequencing reactions were prepared with: 6.5µL of dH2O, 1µL of BigDye, 0.5µL of forward/reverse 
primer and 2µL of purified sample. Then, the sequencing reaction was performed in the termocycler 
with the following conditions: 90°C/20s/1 cycle; 60°C/2minutes/24cycles; 4°C/forever. After this, 
the elimination of BigDye® was made through the application of sequencing sample in a resin 
column, which was centrifuged 4 minutes and 30 seconds at 3290rpm. The collected product was 
loaded into a sequencing plate and analysed on the sequencer ABI PRISM 310 (Applied 
Biosystems®). 
 In sílico analysis 
 In sílico analysis was performed using five tools that predicts the possible consequences of 
the amino acid changes on the structure and function of the proteins using straightforward physical 
and comparative considerations. A mutation is considered pathogenic when 3/5 of in sílico tools 
predict this. The tools used were the following:  
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 PolyPhen2- http://genetics.bwh.harvard.edu/pph2/ (50);  
 Fathmm - http://fathmm.biocompute.org.uk/ (51);  
 MutationTaster- http://www.mutationtaster.org/ (52),  
 MutationAssessor- http://mutationassessor.org/r3/ (53);  
 Provean- http://provean.jcvi.org/index.php (54). 
 
2. Update of the online databases and literature 
The online databases used to do an update of the online databases and literature were 
accessed in September 2017, and were the following: 
 www.erythrocytosis.org (figure 4.1) 
 portal.biobase-international.com (figure 4.2) 
 www.lovd.nl/3.0/ (figure 4.3) 
 exac.broadinstitute.org/ (figure 4.4) 
 www.ensembl.org/index.html (figure 4.5) 
 globin.bx.psu.edu/hbvar/menu.html (figure 4.6) 
 152.99.75.168/KRGDB (figure 4.7) 
 www.ncbi.nlm.nih.gov/pubmed/ (figure 4.8) 
 www.ithanet.eu/ (figure 4.9) 
 
Figure 4- Icons of the online databases. 
4.1- Database Erythrocytosis; 4.2- Database Biobase; 4.3- Database LOVD; 4.4- Database ExAC; 4.5- Database 
Ensembl; 4.6- Database HbVar; 4.7- Database KRGDB; 4.8- Database PubMed; 4.9- Database Ithanet.  
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1. Analysis of the study of 125 patients with CE 
VHL gene mutations 
 In VHL gene 3 different mutations were found (2 missense and 1 nonsense) in 3 different 
patients. All mutations were found in the heterozygous state. Unfortunately, until now was not 
possible to perform a familiar study in these patients to understand the inheritance of the 
mutations with the clinical.  
In Patient 1, a 55-year-old male, the change of C>T nucleotide in position 74 (c.74C>T) leads 
to a Pro>Leu amino acid substitution in codon 25 (p.Pro25Leu) (figure 5), which by in sílico analysis 
was predicted to be benign (table 3).  
 
Figure 5- VHL gene mutations in Patient 1. 
Identification of the VHL c.74 C>T mutation, in heterozygous state, in VHL gene by Sanger Sequencing. 
Table 3- In sílico analisys of the VHL c.74C>T; p.Pro25Leu mutation.  
In sílico tools Result 
PolyPhen2 Benign 
Fathmm Damaging 
MutationTaster Polymorphism 
MutationAssessor Functional Impact Neutral 
Provean Neutral 
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In Patient 2, a 63-year-old male, a change of G>T in position 154 (c.154G>T) results in a stop 
codon, and then a truncation of the long form (pVHL30) of the protein (p.Glu52*) (figure 6). 
 
Figure 6- VHL gene mutations in Patient 2. 
Identification of the VHL c.153 G>T mutation, in heterozygous state, in VHL gene by Sanger Sequencing. 
 
In Patient 3, a 9-year-old female, the change of C>T nucleotide in position 241 (c.241C>T) 
results in a Pro>Ser amino acid substitution in codon 81 (p.Pro81Ser) (figure 7), which by in sílico 
analysis was predicted to be damaging (table 4).  
 
 
Figure 7- VHL gene mutations in Patient 3. 
Identification of the VHL c.241 C>T mutation, in heterozygous state, in VHL gene by Sanger Sequencing. 
Table 4- In sílico analisys of the VHL c.241C>T; p.Pro81Ser mutation.  
In sílico tools Result 
PolyPhen2 Damaging 
Fathmm Damaging 
MutationTaster Polymorphism 
MutationAssessor Functional Impact Low 
Provean Deletirious 
 
25 
 
EGLN1 gene mutations 
 In EGLN1 gene we found 1 missense mutation in heterozygous state, in a male patient with 
38 years. A change of G>C in position 1216 (c.1216 G>C) results in a Gly>Arg amino acid substitution 
in codon 406 (p.Gly406Arg) (Figure8). By in sílico analysis it is predicted to be damaging (table 5). 
 
Figure 8- EGLN1 gene mutations in Patient 4. 
Identification of the EGLN1 c.1216 G>C mutation, in heterozygous state, in EGLN1 gene by Sanger Sequencing. 
 
Table 5- In sílico analisys of the EGLN1 c.1216 G>C; p.Gly406Arg mutation. 
In sílico tools Result 
PolyPhen2 Benign 
Fathmm Damaging 
MutationTaster Disease Causing 
MutationAssessor Functional Impact medium 
Provean Damaging 
 
HBB gene mutations 
 In HBB gene we found a G>A change in 328 position (c.328 G>A), in the heterozygous state 
(figure 9), results in a Val>Met amino acid substitution in codon 110, a known Hb variant with high 
oxygen affinity called Hb San Diego. A presence of a peak in HPLC confirmed a high oxygen affinity 
variant (figure 10).  
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Figure 9- HBB gene mutations in Patient 5. 
Identification of Hb San Diego in HBB gene by Sanger sequencing analysis in patient 5.  
 
 
Figura 10- HPLC of patient 5. 
HPLC showing the presence of a peak that confirms a high oxygen affinity variant (AXA2 X= 41%). 
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2. Mutations and new genes associated with Congenital Erythrocytosis – an 
update of online databases a review of literature  
2.1 Update of online databases 
 CE is a rare disease and consequently the available clinical information on the progression 
of this disease is sparse. There are around 200 mutations associated with CE. Over 100 of this 
mutations are responsible for causing high affinity Hb variants (5,19,55). Currently, there are online 
databases to help establishing the genotype/ phenotype for new mutations or genes founded and 
where clinical and laboratory data can be recorded and compared (5). This section summarizes the 
mutations described so far in the genes associated with CE (8 genes to date).  
 To date, there are 27 mutations (missense/nonsense, small deletions and small insertions) 
described in EPOR gene associated with CE type 1, and the most common mutations are nonsense 
and located in exon 8.  The most recent mutations described are also located in exon 8: p.Cys338Tyr 
and p.Thr341Met. Functional studies of these mutations demonstrate a gain-of-function in the 
EpoR signalling cascades of STAT5, promoting an increase in proliferation and differentiation and a 
decrease in the apoptosis of erythroid progenitors (effect on STAT5 pathways) (56). 
 Mutations in SH2B3 gene are associated with myeloproliferative neoplasms and are 
somatic mutations that are not valued in the presence of CE (57). However, germline mutations 
result in a decrease of LNK activity, which will not act as a negative regulator in the JAK/STAT 
pathway. Some authors show that germline mutations in SH2B3 gene in individuals JAK2-negative 
and diagnosed with IE could justify this. To date, there are 5 missense mutations described in this 
gene related to CE type 1 (58). The first mutations found in SH2B3 gene related to CE was 
p.Glu208Gln and p.Glu400Lys. The first one is located in the PH domain and leads to premature 
termination of the protein translation and the second one is located in the functional SH2 domain 
of LNK (55,58).  
 To date, there are 20 mutations described (19 missense and 1 nonsense mutations) 
associated with CE type 2 (VHL gene mutations). In addition to Chuvash VHL mutations, the 
mutation p.Met54Ile showed a recent syndrome named “Moroccan erythrocytosis”, because it was 
found in three individuals originate from northern Morocco. This suggests a single founder to this 
mutation. All patients are homozygous to this mutation and studies showed a loss-of-function of 
the VHL protein (25). 
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 There are three isoforms of PHD (PHD1, PHD2, PHD3), but just mutations in PHD2 are 
associated with CE (5). The p.Trp334* truncation mutation is located in the catalytic domain, a 
highly conserved region of the protein, and results in a stop codon and consequently in a non-
functional protein. The mutation p.Pro304Leu is also located in the catalytic domain (32,35). To 
date, 30 mutations (missense/nonsense, small deletions and small insertions) in EGLN1 gene, of 
which missense mutations are the most common, were described and associated with CE type 3. 
 There are 12 mutations (11 missense and 1 small deletion mutations) described in EPAS1 
gene related to CE type 4. This gene encodes the transcription factor HIF2α, which is the one 
isoform that is able to induce the EPO transcription. All mutations described leads to a gain-of 
function of the HIF2α and are located in exon 12, except p.Tyr532His mutation that is located in 
exon 9. The carrier patient of this mutation, in addition to having erythrocytosis, also develop 
pheochromocytoma/paraganglioma (5,13,36,55).  
 Regarding high oxygen affinity Hb variants there are more than 100 variants described in 
the HBA and HBB, all compiled essentially in the online database HbVar (globin.bx.psu.edu). The 
most recent high affinity Hb variant described  is called Hb Seoul [HBB: c.259G>A, p.Ala87Thr] (59). 
This variant was observed in a Korean man, who had headaches and nausea, high Hb levels and 
normal EPO levels (63), and can be found in the Korean database KRGDB (152.99.75.168/KRGDB/). 
Only new cases of high oxygen affinity Hb variants are recorded, thus it is impossible to determine 
their incidence and prevalence at the population level.  
 Concerning mutations in BPGM gene there are only four cases described with 
erythrocytosis caused by germline mutations (3 missense mutations and 1 small deletion). The most 
recent mutation described was in a 27-year-old man with erythrocytosis. This missense mutation, 
identified by whole-genome sequencing, resulted in the substitution of arginine with histidine at 
codon 90 (c.269G>A, p.Arg90His) (46). Table 6 summarizes the number of mutations described to 
date for each gene, as well as the type of mutation. Additionally, all mutations are described in 
annex II, except for HBA and HBB genes.  
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Table 6- Resume of the number of mutations described and the type of mutation for each gene. 
GENE MUTANT PROTEIN 
Nº OF MUTATIONS 
DESCRIBED TO DATE 
TYPE OF MUTATION 
EPOR 
Loss of the negative regulatory 
domain 
25 
Missense/ Nonsense 
Small deletions 
SH2B3 
Loss of the inhibitory activity of 
JAK2 
5 Missense 
VHL Loss-of-function 20 Missense/ Nonsense 
EGLN1 Loss-of-function 30 
Missense/ Nonsense 
Small deletions/ insertions 
EPAS1 Gain-of-function 12 
Missense 
Small deletion 
HBB/ HBA Increase Hb affinity for O2 +100 Missense 
BPGM Reduced synthesis of 2,3- BPG 4 
Missense mutations 
Small deletion 
 
 The database erythrocytosis.org aims to register and collect new data of patients with 
congenital or idiopathic erythrocytosis and patients with polycythaemia Vera with rare somatic 
JAK2 mutation. In addition, this database aims to characterize these diseases by clinical 
examination, haematological, biochemical and molecular genetic analyses and collect data about 
clinical course, treatment, amongst other features. Intertwining databases would contribute to 
centralize information and hence simplify and accelerate the understanding of the molecular 
mechanisms of this disease.  Mutations described in annex II were updated in the database 
erythrocytosis.org. 
2.2 New genes associated with CE 
 To date, and as mentioned before, there are eight genes known as associated with CE: 
EPOR, SH2B3, VHL, EGLN1, EPAS1, HBB, HBA and BPGM. However, in 70% of patients suspected of 
having CE the cause is unknown, which reveals that further studies are needed. During the last 
years, scientists have made an effort to find the “missing” genes causing CE (19,55). 
 An article published in 2013, described the study of 70 unrelated patients suspected of 
having CE. All the known casual genes were screened (19). Molecular studies were guided according 
to the data on serum EPO levels, p50, study of haemoglobins by HPLC and familial history, based 
on the algorithm publish by McMullin (19,48). As a result, the authors identified a molecular cause 
in 25/70 patients studied, they found new mutations in JAK2, HBB, EPOR, VHL and EGLN1 genes. 
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Mutations in JAK2 gene were somatic mutations, so this allowed the reclassification as 
polycythaemia Vera in some patients.   
Sequencing of the HBB and HBA genes showed high affinity haemoglobin variants in 14 
patients and a new mutation in EGLN1 was found in a French woman and in three members of her 
family (19). Two mutations were found in VHL gene. The first one was found in homozygous state 
and was associated with CE and the second one was found in heterozygous state. The latter was 
inherited from the father, who has normal haematological parameters. Heterozygous VHL 
mutations has been described in the literature, although the mechanism of this is not understand 
yet. This study reinforces that there must be other genes involved on appearance of erythrocytosis 
(19). 
 Another study carried out in 2016, show the importance of the use of NGS panel for the 
diagnosis of idiopathic erythrocytosis (55). 125 idiopathic erythrocytosis patients were screened, 
with high suspicious of CE. New genes were included in the NGS panel: HIF3A, EGLN2, EGLN3, 
HIF1AN, EPO, KDM6A, GFI1b, BHLHE41, OS9, ZNF197 (55,60). 
 Fifty one exonic variants were identified in 57 patients, and all variants were validated by 
Sanger sequencing. Additionally, new variants were found in novel genes, EPO and BHLHE41, which 
had not been previously associated with CE. A heterozygous variant (a frameshift) found in EPO 
gene showed a possible association of this gene with CE, because the same variant was found in 
patient’s father, who presented with high Hct and Hb levels. In BHLHE41 gene, the variant that were 
found by in sílico analysis was classified as benign. Although the EGLN2, HIF3α and OS9 genes were 
associated with the oxygen-sensing pathway, no variants were identified (55). The NGS results 
reinforce that this technique can be a powerful tool in the genetic investigation of patients with 
erythrocytosis, since with Sanger sequencing just about 20-30% of the patients are correctly 
diagnosed (55). 
 The studies concluded so far have been enlightening and further indicate that the molecular 
causes of erythrocytosis may be varied and in need of identification. The search for candidate genes 
is important and can be a solution for many patients with IE. NGS is therefore a powerful tool 
though the detection of new variants or genes with unknown significance. 
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CE is a rare disease and to date there are 8 genes described and associated with that. 
Although researchers have been made an effort to find new mutations and genes related to CE, 
about 70% of the patients with suspicious of CE have unknown cause or are waiting for the diagnosis  
(5,19,55). Mutations in EPOR and SH2B3 genes are associated with primary CE and are the less 
common. On the other hand, mutation in genes involved in oxygen-sensing pathway (VHL, EGLN1 
and EPAS1 genes) are related to secondary CE and are the most common. Moreover, mutations in 
HBA, HBB and BPGM genes lead to high oxygen affinity variants of Hb, also associated with 
secondary CE (13). In this study we found a molecular cause in 5 of 125 patients studied with 
suspicious of CE. The mutations found (VHL, EGLN1 and HBB genes) are all associated with 
secondary CE.  
VHL mutations 
 VHL mutations are associated with CE type 2 that is characterized by high levels of Hb, Hct. 
However, the EPO levels usually are in a normal range. Haematological parameters of patients with 
VHL mutations are in accordance with CE type 2 (table 7). CE type 2 is a recessive disease and there 
are described cases of individuals heterozygous for VHL mutations, but the mechanism of this is not 
understand so far (55,61). In this study, all VHL mutations were found in heterozygous state. So, a 
familiar study is important to better understand the inheritance of these mutations. However, the 
family’s patients were not able yet.  
Patient 1 show a mutation c.74 C>T; p.Pro25Leu, which are located in the exon 1, between 
the two translational initiation sites (25). This mutation is associated with VHL disease, and the 
majority of disease-causing mutations have been found downstream of the second translational 
initiation site (+54) and has been associated with a sporadic pheochromocytoma, but in some cases 
the pathogenicity was not confirmed. So, there are conflicting data about mutations located in the 
first 53 codons, such as the p.Pro25Leu that could have a pathogenic role. However, this variant is 
consider a rare variant, which may make the genetic counselling difficult (25,55,62). In fact, in sílico 
analysis predict that this mutation is benign. However, Patient 1 shows high levels of Hb and Hct 
with normal levels of EPO that are normal in CE type 2 (table 7).   
 In Patient 2, the mutation c.154 G>T; p.Glu52* leads to a translation termination of the long 
VHL isoform (pVHL30). However, this mutation does not stop the translation of the short VHL 
isoform (pVHL19) because of their translational initiation site +54 (55). Despite nonsense mutations 
in VHL gene are more associated with pheochromocytomas or VHL disease than erythrocytosis, 
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there is a nonsense mutation described (p.Glu10*) related to CE and the p.Glu52* mutation was 
found in a NGS study of idiopathic erythrocytosis patients (5). But, the role of this mutation 
regarding erythrocytosis needs to be elucidate, because of its heterozygous state (5,39,55). Patient 
3 shown a p.Pro81Ser mutation, predicted to be damaging by in sílico analysis. Although this 
missense mutation was described as confer an increased risk of renal cell carcinoma and 
haemangioblastomas, was found here in a patient with erythrocytosis (63).  
Table 7- Clinical features of the patients with VHL gene mutations. 
 
VHL GENE 
 Patient 1 Patient 2 Patient 3 
EPO 7.1 12.4 4.9 
HB 17.5 18.3 13.8 
HCT 51.8 54.0 40.0 
RBC 6.0 5.9 5.8 
AGE 55 63 9 
GENDER Male Male Female 
ORIGEN Portugal Portugal Portugal 
FAMILIAR HISTORY Unknown Unknown Unknown 
MUTATION 
c.74 C>T; p.Pro25Leu 
rs35460768 
c.154 G>T; p.Glu52* 
rs373068386 
c.241C>T; p.Pro81Ser 
rs104893829 
Reference values: 
Male: RBC: 4.50-5.50 x 106/µL; Hb: 13.0-17.0 g/dL; Hct: 40.0-50.0 %; EPO: 4.3-29.0 mUI/mL  
Female: RBC: 4.0-5.2 x 106/µL; Hb: 11.5-15.5 g/dL; Hct: 35.0-45.0 %; EPO: 3.0-30.0 mUI/mL 
EGLN1 mutations 
 PHD2 is the major player in the oxygen-sensing pathway, controlling the stability of HIF2α 
under normoxia/hypoxia conditions (64). Mutations in EGLN1 are associated with CE type 3 and the 
haematological parameters are in accordance with this type of erythrocytosis (table 8). These 
mutations cause a loss-of-function and have an autosomal inheritance (5,35). In fact, Patient 4 had 
familiar history of phlebotomies by paternal side (table 8). By in sílico analysis p.Gly400Arg was 
predicted to be damaging and was described in a patient with erythrocytosis for the first time in 
this document. The majority of mutations in EGLN1 are located in exon 1. However, the p.Gly400Arg 
is located in exon 4 and, to date, there are just one mutation described (p.Arg398*) in this exon and 
result in truncated PHD2 (65).   
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Table 8- Clinical features of the patient with EGLN1 gene mutations. 
EGLN1 GENE 
 Patient 4 
EPO 10.2 
HB 18.3 
HCT 53.2 
RBC 5.56 
AGE 38 
GENDER Male 
ORIGEN Portugal 
FAMILIARY HISTORY 
Father, paternal aunt and paternal cousin are 
under phlebotomy 
MUTATION c.1216 G>C; p.Gly406Arg 
Reference values: 
Male: RBC: 4.50-5.50 x 106/µL; Hb: 13.0-17.0 g/dL; Hct: 40.0-50.0 %; EPO: 4.3-29.0 mUI/mL  
HBB mutations 
 Oxygen is transported to the tissues bound haemoglobin in the blood. The oxygenation and 
deoxygenation of haemoglobin occurs at the heme iron binding site and the affinity for oxygen 
depends on the haemoglobin. Mutations in HBB gene results in a high oxygen affinity haemoglobin 
variants and have an autosomal dominant inheritance (42,69). Patient 5 showed to have a high 
oxygen affinity variant suggested by a decreased P50 (table 9), and its presence was confirmed by 
Sanger sequencing and HPLC, showed an Hb San Diego variant. It was the first time that this variant 
was observed in a Turkish family. The autosomal inheritance was confirmed by the presence of 
erythrocytosis in paternal family’s members (father and grandmother), who have history of 
phlebotomy (table 9). Hb San Diego was observed for the first time in a Filipino family, and since 
them have been described in others families, such as Anglo-Saxon, Japanese , Indian and Caucasian  
(51,71,72,73). 
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Table 9- Clinical features of the patients with HBB mutations. 
HBB GENE 
 Patient 5 
EPO MUI/ML 12.4 
HB G/DL 16.9 
HCT % 50.6 
RBC 106/µL 5.7 
P50 Low 
HPLC AXA2 X=41% 
AGE 15 
GENDER Female 
ORIGEN Turkey 
FAMILIARY HISTORY 
Father (history of phlebotomy), paternal 
grandmother (history of phlebotomy), paternal 
aunt and the son of paternal uncle all have 
erythrocytosis 
MUTATION 
Hb San Diego: β  109 (G11)Val→Met 
rs33969677 
Reference values: 
Female: RBC: 4.0-5.2 x 106/µL; Hb: 11.5-15.5 g/dL; Hct: 35.0-45.0 %; EPO: 3.0-30.0 mUI/mL 
 
Update of online databases and a review of literature 
 Recently, new mutations associated with CE were unveiled/discovered. This new data 
contributed to diagnose patients with CE phenotype but unknown genotype. However, the number 
of patients without diagnosis is still high. For instance, this is the case of heterozygous VHL 
mutations, whose molecular mechanism has not yet been explained. With the development of 
technology, powerful techniques have appeared, such as NGS. This technique allows massive 
sequencing and improved and accelerated the search for known and new genes associated with CE. 
Online databases are important tools to share information among the scientific and medical 
communities. However, these online databases lack important information. Which delays research 
and limits diagnosis in patients with CE-like phenotypes. Updating and intertwining the online 
databases would be of utmost importance. 
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Conclusion  
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In this study we identified a CE molecular aetiology in 5/125 patients studied. We found 
three mutations in VHL gene, one mutation not previously described in EGLN1 gene, and one high 
oxygen affinity Hb variant (Hb San Diego) in HBB gene.  
 One hundred and twenty patients (96%) remain without a definitive diagnosis, which 
demonstrates that a further study is need to better understand this disease. The use of NGS 
technology can be helpful in the study of CE, which will allow to establish a connection with other 
genes that may be involved in CE and that have not been studied so far. In addition, an update and 
a intertwining of the online databases can be useful due to the increase and sharing of information 
between the experts.  
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Final Notes 
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My internship started on September 2016 and ended on September 2017. In addition to 
my project, I had the opportunity to learn new techniques performed in the lab, such as MLPA and 
NGS, amongst others. Also, I had the opportunity to learn about other genetic diseases related to 
red blood cells, which allow me to expand my knowledge on other red blood cell diseases besides 
CE. 
 During this time I collaborated in several projects and attended meetings, which were the 
following: 
 Biobank project in Paediatric Hospital of CHUC; 
 Poster presentation in the Biochemistry Day of University of Aveiro (April 2017) 
(annex III); 
 Poster presentation and oral communication in the 12th MPN&MPNr-EuroNet 
Meeting 2017, Gothenburg, Sweden (May 2017). I was granted by the University 
of Nantes to attend this meeting (abstract in annex IV); 
 Collaboration in a paper: 
Ebru Yılmaz Keskin, Ali Fettah, Ana Catarina Oliveira, Şule Toprak, Andreia Lopes, 
Celeste Bento (2017). “First Observation of Hemoglobin San Diego, a High Oxygen 
Affinity Hemoglobin Variant, in Turkey” (annex V); 
 Poster presentation in “LIX Congreso Nacional de la SEHH y XXXIII Congreso 
Nacional de la SETH en Málaga, España” (October 2017) (abstract in annex VI).  
 
Finally, I was selected to do an internship through an Erasmus+ programme. This 
internship will have place in the University Medical Centre of Utrecht (Netherlands). The 
main goal is to continue this project, and to find/study novel mutations and genes related 
to CE.  
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 Annex I 
 
PCR reactions for EPOR, VHL and EPAS1 genes 
EPOR, VHL, EPAS1 genes 
Master Mix 6.25 µL 
dH2O 4.00 µL 
Q solution 1.25 µL 
Forward primer 0.50 µL 
Reverse primer 0.50 µL 
 
Sequence of primers used for EPOR, VHL and EPAS1 genes 
EPOR gene 
TCCTCTGCCTCCATTGTG 
Exon 7/8 
Forward* 
TACTCAAAGCTGGCAGCAGA Reverse** 
CTCCTGCTCATCTGCTTTGG Forward** 
AGGATGGATTGGGCAGAC Reverse* 
                                       * used in PCR; ** used in Sanger sequencing 
 
VHL gene 
AGCGCGTTCCATCCTCTAC 
Exon 1 
Forward */ ** 
ACGATAGCACGGTCTGAAGC Reverse * 
GAGGTTTCACCACGTTAGCC 
Exon 2 
Forward */** 
TCTCAAAAGCACTTTGGGCT Reverse * 
CCTTGTACTGAGACCCTA 
Exon 3 
Forward * 
CTCAGCTTTTGATGGTACTG Reverse */** 
                                        * used in PCR; ** used in Sanger sequencing 
 
EPAS1 gene 
TCTGCAGGAGCTGAGTTG 
Exon 12 
Forward 
AGAGGCACCCACTAGTAAG Reverse 
                                       * used in PCR; ** used in Sanger sequencing 
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PCR reactions for SH2B3 gene 
SH2B3 gene exon 2  SH2B3 gene exon 3-8  
dH2O 28.0 µL  dH2O 40.0 µL 
Q solution 10.0 µL  Glucose Buffer 5.0 µL 
Q buffer 5.0 µL  dNTPs 1.0 µL 
Forward primer 2.0 µL  Forward primer 1.5 µL 
Reverse primer 2.0 µL  Reverse primer 1.5 µL 
dNTPs 0.8 µL  Taq polymerase 0.4 µL 
Taq polymerase 0.2 µL  - - 
 
Sequence of primers used for SH2B3 gene 
SH2B3 exon 2 
CCAGCACTGGGTGTTATG 
Exon 2 
Forward */ ** 
CAGCTGGAAAGCCATCAC Reverse */ ** 
                                            * used in PCR; ** used in Sanger sequencing 
                                     
     SH2B3 exon 3 to 8 
CTCAGTGTGAATGGTGTTCA 
Exon 3 to 5 
Forward */ ** 
GGGCTACCTTATGTCCTGGG Reverse** 
GTACGCTGGAACCCAGACTC Exon 6 Forward** 
GTCTGCAGCAAGCCTCTACC Exon 7 Reverse** 
TCTGGAAGGAAGGAAAGATCA Exon 8 Reverse */ ** 
                              * used in PCR; ** used in Sanger sequencing 
 
PCR reactions for EGLN1 gene 
EGLN1 gene exon 1  EGLN1 gene exon 2 to 5  
dH2O 28.0 µL  dH2O 28.0 µL 
Q solution 2.5 µL  Glucose Buffer 10.0 µL 
Q buffer 1.25 µL  dNTPs 1.25 µL 
Forward primer 0.75 µL  Forward primer 0.75 µL 
Reverse primer 0.75 µL  Reverse primer 0.75 µL 
DNTPs 0.50 µL  Taq polymerase 0.50 µL 
Taq polymerase 0.2 µL    
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Sequence of primers used for EGLN1 gene 
EGLN1  gene 
TAACGGCCCCTATCTCTCT 
Exon 1 
Forward */ ** 
GGGAAAAGTAAAGGCCAAGC Forward ** 
CGTAAGGAAGACGGACAGAA Reverse */** 
GAAGAATCTAAGTGTAAATCAG 
Exon 2 
Forward */** 
TCTGATAAGACTGTCACAGAC Reverse * 
TTGCAGCTCATCTTCATACTT 
Exon 3 
Forward * 
TATGGTAGGACAGGAGGGAA Reverse */** 
TTAGTCTCCCCTGGTTACTG 
Exon 4 
Forward */** 
TCAGGAAACTCAAGCATAGTC Reverse * 
CAGTGGAATGCAGTAGCAG 
Exon 5 
Forward * 
GAAGATTTTGACTGCTGTGAC Reverse */** 
                              * used in PCR; ** used in Sanger sequencing 
 
PCR reactions for BPGM gene 
BPGM gene exon 1  BPGM gene exon 2 to 3  
dH2O 21.0 µL  Master Mix 6.25 µL 
Q buffer 2.5 µL  dH2O 4.00 µL 
Forward primer 0.5 µL  Q solution 1.25 µL 
Reverse primer 0.5 µL  Forward primer 0.50 µL 
DNTPs 0.5 µL  Reverse primer 0.50 µL 
Taq polymerase 0.2 µL    
 
Sequence of primers used for BPGM gene 
BPGM  gene 
GCCAACTCCTTACTGGTTCA 
Exon 1 
Forward */ ** 
ATGTTGCGAACGTTTACATT Reverse * 
CAGTTGAATATAACTTAGAC 
Exon 2 
Forward */** 
TATACCACTTATTAGAGGTT Reverse */** 
TGATGTAGCACTTGCTGTG 
Exon 3 
Forward */** 
CACTATTCTAATCAGTAGTTCAC Reverse */** 
                              * used in PCR; ** used in Sanger sequencing 
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PCR reactions for HBB gene 
HBB gene 
dH2O 21.0 µL 
Q buffer 2.5 µL 
Forward primer 0.5 µL 
Reverse primer 0.5 µL 
DNTPs 0.5 µL 
Taq polymerase 0.2 µL 
 
Sequence of primers used for HBB gene 
HBB  gene 
GAGCCAAGGACAGGTACGG 
Exon 1 
Forward */ ** 
GAGGTTCTTTGAGTCCTTTG Reverse * 
AGACTCTTGGGTTTCTGA 
Exon 2 
Forward */** 
TAGAATGGGAAACAGACGAATG Reverse * 
CAATGTATCATGCCTCTTTGCACC 
Exon 3 
Forward */** 
CCATGAAAGAAGGTGAGGCTGC Reverse * 
                              * used in PCR; ** used in Sanger sequencing 
 
PCR reactions for HBA gene 
HBA gene 
dH2O 28.0µL 
Q solution 10.0µL 
Q buffer 5.0µL 
Forward primer 0.8µL 
Reverse primer 2.0µL 
DNTPs 2.0µL 
Taq polymerase 0.2µL 
 
Sequence of primers used for HBA gene 
HBA  gene 
GGTGCACGAGCCGACAGCGC HBA1/HBA2 Forward * 
CTGGACTTCGCGGTGGCT HBA1 Reverse * 
GCAGGCCTGGCACCTCTCAG HBA2 Reverse * 
TCCCCACAGACTCAGAGAGAAC HBA1/HBA2 Exon 1 Forward ** 
ATGTTCCTGTCCTTCCCCAC HBA1/HBA2 Exon 2 Forward ** 
AGTTCCTGGCTTCTGTGAGC HBA1/HBA2 Exon 3 Forward ** 
CGCCCACTCAGACTTTATTCAAAG HBA1 Reverse ** 
TTATTCAAAGACCAGGAAGGGCCG HBA2 Reverse ** 
                              * used in PCR; ** used in Sanger sequencing 
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Annex II 
 
 
 
EPOR mutations 
Nucleotide exchanged Protein effect References Year 
c.634G>T p.Gly212Cys (70) 2014 
c.1013G>A p.Cys338Tyr (71) 2016 
c.1023C>T p.Thr341Met (71) 2016 
c.1138C>G p.Pro380Ala (19) 2013 
c.1141_1142delCC p.Pro381Glnfs*2 (72) 2008 
c.1195G>T p.Glu399* (73) 2002 
c.1234delT p.Ser412Argfs*41 (74) 2011 
c.1235C>A p.Ser412* (19) 2013 
c.1242_1276del35 p.Ser415Hisfs*18 (19) 2013 
c.1249G>T p.Glu417* (75) 2010 
c.1252_1255delGGAG p.G418Profs*34 (76) 2004 
c.1271_1272delTT p.Phe424* (72) 2008 
c.1273G>T p.Glu425* (14) 2001 
c.1278C>G p.Tyr426* (77) 1998 
c.1281dupT p.Ile428Tyrfs*17 (78) 1997 
c.1282_1289dupATCCTGGA p.Asp430Glufs*26 (79) 1999 
c.1285delC p.Leu429Trpfs*24 (72) 2008 
c.1288dupG p.Asp430Glyfs*15 (80) 1995 
c.1299_1305delCCAGCTC p.Gln434Cysfs*17 (81) 1997 
c.1300C>T p.Gln434* (82) 1997 
c.1311_1312delTC p.Pro438Metfs*6 (19) 2013 
c.1310G>A p.Arg437His (19) 2013 
c.1316G>A p.Trp439* (83) 1993 
c.1317G>A p.Trp439* (84) 2007 
c.1362C>G p.Tyr454* (85) 2016 
c.1460A>G p.Ans487Ser (86) 1996 
c.1462C>T p.Pro488Ser (87) 1994 
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SH2B3 mutations 
Nucleotide exchanged Protein effect References Year 
c.232G>A p.Glu78Lys (55) 2016 
c.622G>C p.Glu208Gln (55) 2016 
c.901G>A p.Glu301Lys (55) 2016 
c.1198G>A p.Glu400Lys (88) 2011 
c.1244G>C p.Arg415Pro (55) 2016 
VHL mutations 
Nucleotide exchanged Protein effect References Year 
c.28G>T p.Glu10* (5) 2014 
c.162G>C p.Met54Ile (25) 2015 
c.235C>T p.Arg79Cys (89) 2005 
c.241C>G p.Pro81Ala (5) 2014 
c.311G>T p.Gly104Val (90) 2005 
c.370A>G p.Thr124Ala (91) 2013 
c.376G>A p.Asp126Asn (92) 2011 
c.376G>T p.Asp126Asn (93) 2003 
c.388G>C p.Val130Leu (93) 2003 
c.413C>T p.Pro138Leu (94) 2013 
c.430G>A p.Gly144Arg (95) 2005 
c.449A>G p.Asn150Ser (96) 2015 
c.524A>G p.Tyr175Cys (89) 2005 
c.548C>T p.Ser183Leu (92) 2011 
c.562C>G p.Leu188Val (93) 2003 
c.571C>G p.His191Asp (93) 2003 
c.574C>A p.Pro192Thr (5) 2014 
c.574C>T p.Pro192Ser (93) 2003 
c.586A>G p.Lys196Glu (19) 2013 
c.598C>T p.Arg200Trp (97) 2002 
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EPAS1 mutations 
Nucleotide exchanged Protein effect References Year  
c.1121T>A p.Phe374Tyr (36) 2012 
c.1594T>C p.Tyr532His (55) 2016 
c.1597A>G p.Ile533Val (98) 2013 
c.1601C>T p.Pro534Leu (99) 2009 
c.1603A>G p.Met535Val (100) 2012 
c.1604T>C p.Met535Thr (38) 2012 
c.1605G>A p.Met535Ile (101) 2008 
c.1609G>A p.Gly537Arg (38)  2008 
c.1609G>T p.Gly537Trp (37) 2008 
c.1617C>G p.Asp539Glu (102) 2010 
c.1620C>G p.Phe540Leu (100) 2012 
c.49_51delGAG p.del17Glu (55) 2016 
BPGM mutations 
Nucleotide exchanged Protein effect References Year 
c.185G>A p.Arg62Gln (16) 2004 
c.268C>T p.Arg90Cys (103) 1992 
c.268G>A p.Arg90His (46) 2014 
c.61delC p.Arg21Valfs*28 (103) 1992 
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EGLN1 mutations 
Nucleotide exchanged Protein effect References Year 
c.12C>A p.Asp4Glu (104) 2013 
c.380G>C p.Cys127Ser (105) 2014 
c.413T>C p.Val138Ala (70) 2014 
c.471G>C p.Gln157His (106) 2011 
c.493G>T p.Pro165Ser (70) 2014 
c.494delC p.Pro165fs (107) 2016 
c.599C>A p.Pro200Gln (65) 2012 
c.606delG p.Met202Ilefs*72 (72) 2008 
c.609C>G p.Asn203Lys (108) 2012 
c.610G>G p.Lys204Glu (5)  2014 
c.661C>T p.Gln221* (32) 2016 
c.678dupG Arg227Alafs*20 (32) 2016 
c.715C>T p.Gln239* (32) 2016 
c.760G>C p.Asp254His (65) 2012 
c.835_848del14 p.Leu279Thrfs43* (70) 2014 
c.836T>C p.Leu279Pro (55) 2016 
c.840dupA p.Arg281Thrfs*4 (72) 2008 
c.853G>C p.Gly285Arg (5)  2014 
c.872A>T p.Lys291Ile (108) 2012 
c.911C>T p.Pro304Leu (32) 2016 
c.950C>G p.Pro317Arg (34) 2006 
c.1000T>C p.Trp334Arg (19) 2013 
c.1001G>A p.Trp334* (32) 2016 
c.1010dupA p.Val338Glyfs*18 (5)  2014 
c.1111C>T p.Arg371Cys (32) 2016 
c.1112G>A p.Arg371His (65) 2007 
c.1121A>G p.His374Arg (31) 2008 
c.1129C>T p.Gln377* (72) 2008 
c.1192C>T p.Arg398* (65) 2012 
c.1267A>G p.Lys423Glu (108) 2012 
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Annex IV 
Congenital Erythrocytosis: identification of novel mutations in EGLN1 (PHD2), SH2B3 
(LNK) and VHL genes 
Andreia Lopes1,2*, Janet Pereira1, Ana Catarina Oliveira1, Luís Relvas1, Elizabete Cunha1, Tabita 
Magalhães Maia1, Celeste Bento1,3, Letícia Ribeiro1 
 
1Unidade de Eritropatologia e Metabolismo do Ferro, Serviço de Hematologia Clínica, Centro 
Hospitalar e Universitário de Coimbra, Coimbra, Portugal** 
2Departamento de Química, Universidade de Aveiro, Aveiro, Portugal 
3CIAS, Departamento de Ciências da Vida, Universidade de Coimbra, Coimbra, Portugal 
*alopes90@ua.pt; ** R. Dr. Afonso Romão, 3000-362 Coimbra, Portugal 
 Congenital Erythrocytosis (CE) may either be primary or secondary to elevated Epo 
concentrations. The only known form of primary CE is caused by mutations in the EPOR gene. 
Secondary CE can be caused by congenital defects such as Hbs with increased oxygen affinity, due 
to mutations in the HBB, HBA or BPGM, or from defects in the components of the oxygen-sensing 
pathway, namely mutations in EGLN1, EPAS1 and VHL. Despite important discoveries in the 
molecular pathogenesis of CE, in about 70% of the patients the genetic causes remain to be 
identified. 
 We studied 54 subjects with CE, followed in our hospital or referred from other hospitals, 
during the last 2 years. Laboratory testing was guided by the clinical history and EPO levels and 
included: HBB, HBA, BPGM, EPOR, SH2B3, VHL, EGLN1 and EPAS1 Sanger sequencing.  
 In this study we identified: 2 mutations in EGLN1, p.Phe366Leu results in a substitution in a 
highly conserved region of the PHD2 and was found in a father and son (64 and 39 yo), and 
Arg227Alafs*20 that was observed in a 34 yo male; 3 mutations in SH2B3: p.Arg80Cys, present in 
phenylalanine zipper which is responsible to mediate the dimerization of LNK, p.Pro308* that 
belongs to PH domain; and p.Glu400Lys already described. SH2B3 mutations were found in a 67 yo 
female, 18 yo male and 85 yo female respectively; 1 mutation in VHL, observed in a 55 yo male and 
results in a p.Pro25Leu substitution. All mutations were found in heterozygous state. 
 We were able to identify the CE molecular aetiology in 6/54 subjects studied. We found 1 
mutation already described and 5 new mutations, which by in silico analysis were predicted to be 
damaging. However, 48 patients still remain without definitive diagnostic. This demonstrates that 
further study is needed to better understand this disease. The use of NGS technology can be helpful 
in the study of CE, which will allow establishing a connection with other genes that may be involved 
in CE and that have not been studied so far. 
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Annex VI 
Eritrocitosis Congénita: Identificación de mutaciones en los genes EGLN1 (PHD2), VHL y 
HBB en un estudio de 50 pacientes 
Lopes A.1,2, Pereira J.1, Oliveira A.1, Relvas L.1, Cunha E.1, Magalhães Maia T.1, Bento C.1,3, Ribeiro L.1 
1Unidade de Eritropatologia e Metabolismo do Ferro, Serviço de Hematologia Clínica, Centro 
Hospitalar e Universitário de Coimbra, Coimbra, Portugal 
2Departamento de Química, Universidade de Aveiro, Aveiro, Portugal 
3CIAS, Departamento de Ciências da Vida, Universidade de Coimbra, Coimbra, Portugal 
Introducción: La Eritrocitosis Congénita (EC) puede ser primaria o secundaria a elevadas 
concentraciones de eritropoyetina (Epo). La única forma conocida de EC primaria es causada por 
mutaciones en el gene EPOR y recientemente se ha asociado el gen SH2B3. La EC secundaria puede 
ser causada por defectos congénitos como Hbs con mayor afinidad por el oxígeno, debido a 
mutaciones en HBB, HBA o BPGM, o por defectos en los componentes de la vía de detección de 
oxígeno, a saber mutaciones en EGLN1, EPAS1 y VHL. A pesar de que ya se han identificado las 
causas que están en la base de la EC, cerca del 70% de los individuos aún permanecen sin 
diagnóstico. 
Métodos: Se estudiaron 50 sujetos con EC, seguidos en nuestro hospital o remitidos de otros 
hospitales, durante los últimos 2 años. Las pruebas de laboratorio se basaron en la historia clínica 
y los niveles de Epo e incluyeron secuenciación de Sanger de los genes: HBB, HBA, BPGM, EPOR, 
SH2B3, VHL, EGLN1 y EPAS1. 
Resultados: En este estudio hemos identificado: 2 mutaciones en EGLN1, p.Phe366Leu que causa 
una sustitución en una región altamente conservada de la PHD2 y se encontró en un padre y su hijo 
(64 y 39 años), y la p.Arg227Alafs * 20 que se observó en un hombre de 34 años. En VHL se 
encontraron 2 mutaciones: p.Pro25Leu, en heterozigotia, en un hombre de 55 años. Esta mutación 
que se clasifica como una variante no patogénica. La segunda mutación encontrada fue p.Glu52 *, 
que a pesar de ya estar descrita, su papel aún no está claro cuando asociada a eritrocitosis y en 
heterozigotia. Esta mutación se observó en un hombre de 63 años. Por fin, en HBB identificamos 
una variante de Hb- Hb de San Francisco- en una niña de 16 años. 
Conclusiones: En nuestro estudio identificamos la probable causa genética de la EC en 5/50 
pacientes. Mientras, 45 pacientes permanecen sin diagnóstico, lo que demuestra que se necesitan 
más estudios para comprender mejor esta enfermedad. El uso de la tecnología NGS puede ser útil 
en el estudio de EC, lo que permitirá establecer una conexión con otros genes que pueden estar 
implicados en EC y que no han sido estudiados hasta el momento.  
 
